Publication:

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer

Loading...
Thumbnail Image

Open/View Files

Date

2017

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Nature Publishing Group
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Betancur, P. A., B. J. Abraham, Y. Y. Yiu, S. B. Willingham, F. Khameneh, M. Zarnegar, A. H. Kuo, et al. 2017. “A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer.” Nature Communications 8 (1): 14802. doi:10.1038/ncomms14802. http://dx.doi.org/10.1038/ncomms14802.

Abstract

CD47 is a cell surface molecule that inhibits phagocytosis of cells that express it by binding to its receptor, SIRPα, on macrophages and other immune cells. CD47 is expressed at different levels by neoplastic and normal cells. Here, to reveal mechanisms by which different neoplastic cells generate this dominant ‘don't eat me' signal, we analyse the CD47 regulatory genomic landscape. We identify two distinct super-enhancers (SEs) associated with CD47 in certain cancer cell types. We show that a set of active constituent enhancers, located within the two CD47 SEs, regulate CD47 expression in different cancer cell types and that disruption of CD47 SEs reduces CD47 gene expression. Finally we report that the TNF-NFKB1 signalling pathway directly regulates CD47 by interacting with a constituent enhancer located within a CD47-associated SE specific to breast cancer. These results suggest that cancers can evolve SE to drive CD47 overexpression to escape immune surveillance.

Description

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories